ArticleBMJ case reports2026
Prolonged ventricular fibrillation treated with nifekalant in fulminant myocarditis following late-onset coronavirus disease 2019.
Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulminant myocarditis (FM) is a life-threatening inflammatory cardiac disease that can rapidly progress to cardiogenic shock or fatal arrhythmias. Delayed-onset FM following coronavirus disease 2019 (COVID-19) infection is rare and cases complicated by sustained ventricular fibrillation (VF) are exceptional.A previously healthy man in his late teens developed dyspnoea and complete atrioventricular block after COVID-19 infection. Echocardiography revealed a left ventricular ejection fraction of 30%. Despite veno-arterial extracorporeal membrane oxygenation and Impella CP support, he developed persistent VF lasting for five days, refractory to amiodarone and repeated defibrillation. Continuous intravenous infusion of nifekalant hydrochloride terminated VF and converted to sinus rhythm. Endomyocardial biopsy demonstrated CD68
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.